INTRODUCTION
Pneumocystis pneumonia (PCP) is a rare but critical complication in immunosuppressed patients [1] . It was primarily revealed in human immunodeficiency virus (HIV) positive patients in the 1980s [2] . In the following years, PCP cases enlarged in patients with rheumatoid arthritis (RA) being treated with disease-modifying antirheumatic drugs (DMARDs), with high mortality rates recorded [3, 4] . More lately, PCP cases have likewise been reported throughout management with biologic agents targeted at precise molecules [5, 6] . Whereas immunosuppressive treatment is recognized as a risk factor for the progress of pneumocystis pneumonia, through lymphocyte count suppression [7] , a former study described that pneumocystis pneumonia might develop throughout management with biologic agents in patients with rheumatoid arthritis, without apparent lymphocytopenia [8] . This recommends that distinct mechanisms can be intricate in the development of pneumocystis pneumonia throughout management with biologic agents. Nonetheless, little is known about the differences in the clinical characteristics of pneumocystis pneumonia throughout treatment with biologic agents in comparison with nonbiologic disease-modifying antirheumatic medications. The purpose of the present study was to clarify the differences in the clinical characteristics of pneumocystis pneumonia between patients being treated with biologic agents and patients being treated with nonbiologic disease-modifying antirheumatic medications.
MATERIALS AND METHODS
The study was a retrospective, observational clinical study conducted at our institution with approval by the institutional ethics committee. From a total of 220 consecutive patients with RA who visited our institution between August 2016 and November 2016, all patients who were diagnosed with pneumocystis pneumonia were enrolled in the analysis. PCP was diagnosed as definite when patients met all the following criteria [9] :  A-clinical manifestations and findings compatible with PCP on chest computed tomography (CT),  B-microscopic detection of pneumocystis jirovecii or positive polymerase chain reaction test results
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for pneumocystis jirovecii DNA in respiratory specimens, C-increased β-D-glucan serum levels. Pneumocystis pneumonia was diagnosed as probable when patients met criterion (a), with either criterion (b) or (c) in addition [9] . The manufacturer recommended that the upper normal limit for serum β-D-glucan was 11.3 pg/mL, but we defined 31.1 pg/mL as a cut-off value in this study to exclude pneumocystis jirovecii colonization, based on a previous study [10] . , and β-D-glucan) were retrospectively reviewed. The severity of pneumonia was evaluated with the oxygenation index determined from the arterial oxygen tension and the fraction of inspired oxygen (PaO2/FiO2 ratio).
The study was done according to the ethical board of King Faisal university.
Statistical analysis
Continuous variables were expressed as mean ± standard error. Mann-Whitney U test and Fisher's exact test were used to compare continuous and categorical variables, respectively. The relationships between variables were analyzed by Spearman correlation coefficient. SPSS version 22.0 was used for all statistical analyses, and P < 0.05 was considered as significant.
RESULTS
Figure 1 is an outline showing how patients were recruited for this study. Of the 220 patients with rheumatoid arthritis, 112 patients received biologics. Twenty-one patients were suspected to have PCP. Of these 21 patients, 9 patients were excluded from the analysis because they did not satisfy the diagnostic criteria stated above. Consequently, a total of 12 patients were enrolled in this study (definite PCP, = 8, and probable PCP, =4) and divided into two groups according to their treatment for rheumatoid arthritis (the biologics group, = 6 (definite, =3 and probable, =3), and the nonbiologics group, = 6 (definite, =4 and probable, =2)). Table 1 . The patients in the nonbiologics group were significantly older than those in the biologics group (71.1 versus 65.1 years, = 0.039), but no significant differences were found in smoking history (33.3% versus 33.3%, P = 1.00), duration from onset of symptoms to PCP diagnosis (7.5 versus 10.9 days, P = 0.37 ), Whereas the biologics group had significantly lower serum levels of β-D-glucan (101 versus 225 pg/mL, P = 0.037) and CRP (5.12 versus 10.5 mg/dL, P= 0.039) than the nonbiologics group, the biologics group had significantly higher lymphocyte counts than the nonbiologics group (1431 versus 583 cells/μL, P = 0.029), implying that patients on biologics develop pneumocystis pneumonia with almost normal lymphocyte counts accompanied with low -D-glucan levels. No significant differences were found in total white blood cell counts (5349 versus 7211 cells/μL, P= 0.47), the levels of IgG (1120 versus 901 cells/ μL, P = 0.24), LDH (296 versus 387 U/L, P = 0.11), KL-6 (629 versus 1010 U/mL, P = 0.22), and the PaO2/FiO2 ratio (291 versus 279, P = 0.49). Additionally, we analysed the relationship between the PaO2/FiO2 ratio, which is used to evaluate the severity of pneumonitis, and laboratory findings. In all the patients (n = 12), serum levels of CRP and LDH negatively correlated with the PaO2/FiO2 ratio, while lymphocyte counts and serum albumin levels positively correlated with the PaO2/FiO2 ratio. Nevertheless, when we performed the same analysis separately in the biologics group and in the 213 nonbiologics group, only the CRP levels negatively correlated with the PaO2/FiO2 ratio in both groups. The significant correlation with the other variables, except for LDH in the nonbiologics group, was no longer detected in either group, suggesting that the CRP level was the most important index for assessing the severity of PCP.
DISCUSSION
In the present study, we discovered that, in patients with rheumatoid arthritis who are being managed with biologic agents, pneumocystis pneumonia developed with almost normal lymphocyte counts and lower β-D-glucan levels, while in those being managed with nonbiologic DMARDs, pneumocystis pneumonia was marked by high β-D-glucan levels with apparent lymphocytopenia. The findings suggest that the pathophysiology of pneumocystis pneumonia in patients being treated with biologic agents is different from that in patients being treated with nonbiologic DMARDs. Moreover, we found that only serum CRP levels, but not β-D-glucan levels, reflected the severity of pneumocystis pneumonia in patients with rheumatoid arthritis.
Supposing that β-D-glucan levels designate the growth of pneumocystis jirovecii and lymphocyte counts represent the degree of concession on the immune system, the differences in the burden of pneumocystis jirovecii and immunosuppression in our study recommend that the mechanism of pneumocystis pneumonia development with the utilization of biologic agents is noticeably dissimilar from that with the use of nonbiologic DMARDs. An earlier study described that alveolar macrophages are crucial in mediating the clearance of pneumocystis jirovecii from the lungs [11] , through the production of a large amount of tumour necrosis factor-α (TNF-α) [12] . An experiment on murine models of pneumocystis pneumonia proved that the clearance of Pneumocystis jirovecii infection was reduced when TNF-α was neutralized by TNF-α inhibitors [13] . Consequently, pneumocystis pneumonia development throughout the use of biologic agents, which unswervingly inhibit cytokines such as TNF-α, might be initiated by impaired primary host immune reactions of alveolar macrophages, rather than by lymphocyte suppression. Contrariwise, the pathogenesis of pneumocystis pneumonia during the use of nonbiologic DMARDs can be ascribed to immunosuppression that manifests with lymphocytopenia. In fact, lymphocytes play a vital role in host defense against pneumocystis jirovecii, both in humans and in murine models, with an increased hazard of pneumocystis pneumonia development in patients with evidently reduced lymphocyte counts [14, 15] . Unswerving with these reports, the present study presented that there is a significant correlation between lower lymphocyte counts and the burden of pneumocystis jirovecii, indicated by serum β-D-glucan levels in patients receiving nonbiologic DMARDs.
Respiratory impairment is more strictly related with the extent of lung irritation than with the amount of pneumocystis jirovecii burden in HIVinfected patients, and the same finding was reported in non-HIV-infected patients [16] . Correspondingly, the present study presented that respiratory impairment, represented by the PaO2/FiO2 ratio, was related to the levels of serum CRP, but not to the levels of serum β-D-glucan in both the biologics and the nonbiologics groups. pneumocystis pneumonia severity can be a result of lung inflammation, disturbing gas exchange, and may be unaffected by the quantity of pneumocystis jirovecii.
LIMITATIONS
This is a retrospective, observational study with a small sample size, even though the initial sample of patients with rheumatoid arthritis, with or without pneumocystis pneumonia , was of a large number. Correspondingly, there is a little opportunity that some lost-to-follow-up patients may have developed pneumocystis pneumonia ; nevertheless, we believe they would be very few considering the low occurrence of pneumocystis pneumonia and would not change the outcomes of our study. We believe that the present study is vital for increasing the understanding of this rare, critical complication of pneumocystis pneumonia in patients with rheumatoid arthritis being treated with biologic agents. Further prospective studies in larger cohorts of patients are needed to confirm our results.
CONCLUSION
In patients with rheumatoid arthritis being treated with biologic agents, pneumocystis pneumonia develops with nearly normal lymphocyte counts and low β-D-glucan levels. Rheumatologists should recognize these newly identified characteristics of this is rare but critical complication during treatment with biologic agents to ensure early diagnosis and appropriate treatment.
